X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (3) 3
aged (3) 3
aged, 80 and over (3) 3
female (3) 3
humans (3) 3
index medicus (3) 3
middle aged (3) 3
basal cell carcinoma (2) 2
biphenyl compounds - administration & dosage (2) 2
biphenyl compounds - adverse effects (2) 2
cancer (2) 2
carcinoma, basal cell - drug therapy (2) 2
care and treatment (2) 2
double-blind method (2) 2
hematology, oncology and palliative medicine (2) 2
male (2) 2
metastasis (2) 2
oncology (2) 2
open-label (2) 2
pyridines - administration & dosage (2) 2
pyridines - adverse effects (2) 2
skin (2) 2
skin neoplasms - drug therapy (2) 2
skin neoplasms - pathology (2) 2
vismodegib (2) 2
610 medicine & health (1) 1
adjuvant treatment (1) 1
advanced basal cell carcinoma (1) 1
analysis (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
basal cell carcinoma outcomes with lde225 treatment study (1) 1
bevacizumab (1) 1
biphenyl compounds (1) 1
biphenyl compounds - therapeutic use (1) 1
breast cancer (1) 1
breast neoplasms - chemistry (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - mortality (1) 1
carcinoma, basal cell (1) 1
carcinoma, basal cell - pathology (1) 1
carcinoma, basal cell - radiotherapy (1) 1
carcinoma, basal cell - secondary (1) 1
carcinoma, basal cell - surgery (1) 1
chemotherapy, adjuvant (1) 1
clinical trials (1) 1
colon-cancer (1) 1
corn (1) 1
dermatology (1) 1
dermatology clinic (1) 1
disease progression (1) 1
disease-free survival (1) 1
dose-escalation (1) 1
drug dosages (1) 1
drug therapy (1) 1
efficacy (1) 1
european-organization (1) 1
guidelines (1) 1
hedgehog pathway (1) 1
hedgehog pathway inhibitor (1) 1
hedgehog-pathway (1) 1
inhibitor (1) 1
integumentary system (1) 1
kaplan-meier estimate (1) 1
locally advanced basal cell carcinoma (1) 1
management (1) 1
medical colleges (1) 1
medical research (1) 1
medical treatment (1) 1
medicine, experimental (1) 1
metastatic basal cell carcinoma (1) 1
multicenter (1) 1
mutations (1) 1
neoadjuvant chemotherapy (1) 1
neoplasm metastasis (1) 1
neoplasm recurrence, local - drug therapy (1) 1
neoplasm recurrence, local - pathology (1) 1
neoplasm recurrence, local - radiotherapy (1) 1
neoplasm recurrence, local - surgery (1) 1
patient outcomes (1) 1
patients (1) 1
plus docetaxel (1) 1
pyridines (1) 1
pyridines - therapeutic use (1) 1
quality-of-life (1) 1
radiation therapy (1) 1
receptor, erbb-2 - analysis (1) 1
receptors, estrogen - analysis (1) 1
receptors, progesterone - analysis (1) 1
resistance (1) 1
skin neoplasms (1) 1
skin neoplasms - radiotherapy (1) 1
skin neoplasms - surgery (1) 1
smoothened receptor (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.